株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

D型肝炎:パイプライン製品の分析

Hepatitis D - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 245993
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
D型肝炎:パイプライン製品の分析 Hepatitis D - Pipeline Review, H2 2016
出版日: 2016年10月12日 ページ情報: 英文 77 Pages
概要

D型肝炎とは、D型肝炎ウイルス(HDV、デルタウイルス)が感染し、肝臓を腫れ上がらせるという感染症です。主な症状として、皮膚・眼球の黄疸や関節痛・腹痛、吐き気、食欲不振、倦怠感などがあります。主なリスク要因には、多量の輸血や、静注(IV)薬物・注射薬の乱用、妊娠中の感染などが含まれています。

当レポートでは、世界各国でのD型肝炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

D型肝炎の概要

治療薬の開発

  • D型肝炎向けパイプライン製品:概要
  • D型肝炎向けパイプライン製品:比較分析

各企業で開発中のD型肝炎治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

D型肝炎治療薬:開発中の製品の一覧(企業別)

D型肝炎治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • BioDiem Ltd
  • Biogenomics Limited
  • Eiger BioPharmaceuticals, Inc.
  • Globeimmune, Inc.
  • Johnson & Johnson
  • REPLICor Inc.
  • SomaGenics Inc.

D型肝炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 分子の種類別

薬剤のプロファイル

  • ALN-HDV
  • EBP-921
  • GI-18000
  • hepatitis D vaccine
  • interferon alfa-2b (recombinant)
  • lonafarnib
  • Myrcludex-B
  • REP-9-AC'
  • RNAi Oligonucleotide for Hepatitis D
  • tipifarnib

D型肝炎治療薬:パイプライン製品の最新動向

D型肝炎治療薬開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8525IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2016, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Hepatitis D.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis D Overview
  • Therapeutics Development
    • Pipeline Products for Hepatitis D - Overview
    • Pipeline Products for Hepatitis D - Comparative Analysis
  • Hepatitis D - Therapeutics under Development by Companies
  • Hepatitis D - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis D - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hepatitis D - Products under Development by Companies
  • Hepatitis D - Products under Investigation by Universities/Institutes
  • Hepatitis D - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Eiger BioPharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Globeimmune, Inc.
    • REPLICor Inc.
    • Rodos BioTarget GmbH
    • SomaGenics, Inc.
    • Spring Bank Pharmaceuticals, Inc.
  • Hepatitis D - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-HDV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARC-520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GI-18000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lonafarnib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myrcludex-B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peginterferon lambda-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBT-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REP-2165 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RNAi Oligonucleotide for Hepatitis D - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-9200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vanitaracin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis D - Dormant Projects
  • Hepatitis D - Product Development Milestones
    • Featured News & Press Releases
      • Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
      • Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV - 3 Study at National Institutes of Health
      • Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology
      • May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection
      • Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B
      • Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016
      • Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting
      • Mar 23, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection
      • Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
      • Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 3) Study at National Institutes of Health
      • Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School in Hannover, Germany
      • Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients
      • Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin
      • Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June
      • Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis D, H2 2016
  • Number of Products under Development for Hepatitis D - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016
  • Hepatitis D - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016
  • Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016
  • Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Hepatitis D - Pipeline by Globeimmune, Inc., H2 2016
  • Hepatitis D - Pipeline by REPLICor Inc., H2 2016
  • Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2016
  • Hepatitis D - Pipeline by SomaGenics, Inc., H2 2016
  • Hepatitis D - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hepatitis D - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hepatitis D, H2 2016
  • Number of Products under Development for Hepatitis D - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top